Subscribe to Newsletter

November 2019 Issue of The Medicine Maker

Welcome to the November issue! Half a million lives have been lost to the US opioid crisis over the past 30 years: our cover feature examines pharma’s role. In Upfront, you can find out how researchers are harnessing bacterial viruses to improve drug delivery to the brain; while Nik Kotecha gives his thoughts on mitigating Brexit supply chain risks in In My View. In Business, Letrishka Anthony asks whether ADCs could finally move to the forefront in the targeted therapy space; and we Sit Down With Tony Hitchcock, Technical Director of Cobra Biologics, Keele, UK.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

Discovery & Development Dosage Forms

Attack of the Horse Pills

| Stephanie Vine

Why are people still being prescribed giant tablets?

Discovery & Development Drug Delivery

Beyond the Barrier

| Maryam Mahdi

Can bacterial viruses improve drug delivery to the brain?

Business & Regulation Standards & Regulation

Relieving the Burden

| Maryam Mahdi

The EMA has granted conditional marketing approval for Ervebo, the first vaccine to protect against Ebola.

Manufacture Quality & Compliance

Trials of a Medicine Maker

Step into the design space and your life will be changed forever.

Manufacture Technology and Equipment

The Risk Calculator

| Maryam Mahdi

Elsevier aims to help protect patients against adverse drug reactions with its updated drug-drug interaction calculator.

Business & Regulation Business Practice

A Bitter Pill

| Maryam Mahdi

A new campaign highlights how far businesses have to go to close the gender pay gap – and pharma is no exception.

Business & Regulation Business Practice

Business in Brief

| Stephanie Vine

Continuous processing, exporting generics and alleviating drug shortages… what’s new for pharma in business?

Manufacture Bioprocessing - Single Use Systems

The Human Factor

| Andrew Kit

Single-use systems must be designed with the end-user in mind.

Manufacture Supply Chain

Post-FMD, Post-Problems?

| Allan Bowyer

What challenges are companies facing in the post-FMD climate?

Business & Regulation Business Practice

Leading by Example

| Nik Kotecha

Brexit is a serious challenge for UK businesses trading with the EU.

Manufacture Advanced Medicine

Getting Ahead of the Game in Cell and Gene Therapy

| Carol Knevelman

CGT developers: consider, at an early stage, how to produce your product at scale or you may run into problems with commercial manufacturing.

Business & Regulation Business Practice

The (Human) Cost of Greed

| James Strachan

The US opioid crisis has claimed the lives of hundreds of thousands. We examine pharma’s role.

Manufacture Bioprocessing - Upstream & Downstream

When One Size Doesn't Fit All

| Alison Porter

More complex proteins are coming down the pipe! Next-generation protein expression will require a toolbox of next-generation solutions.

Business & Regulation Trends & Forecasts

Tenacious ADCs

| Letrishka Anthony

After a new approval and multi-million dollar deals, are ADCs finally moving to the forefront in the targeted therapy space?

Manufacture Bioprocessing - Upstream & Downstream

Next-Generation Bioprocessing and the Implications for Viral Safety

| Kathy Remington, Michael Phillips

With the focus on next generation bioprocessing, it is important that manufacturers do not forget to re-examine their approach to viral safety.

Business & Regulation Profession

Welcoming Change

| Maryam Mahdi

Tony Hitchcock discusses his career and the evolution of the gene therapy market.

Other issues of 2019